Literature DB >> 2151734

Urokinase-dependent cell surface proteolysis and cancer.

F Blasi1, P Verde.   

Abstract

Plasmin formation is an important and complex process in vivo. It involves two enzymes, two inhibitors, the substrate and specific receptors. Plasmin formation, dependent on the urokinase-type plasminogen activator (uPA), is discussed in its biochemical, regulatory and physiological aspects and its involvement in cancer malignancy analysed. The role of cell surface plasminogen activation in the processes of extracellular matrix degradation, basement membrane dissolution and cancer invasiveness and metastasis is now established in a variety of model systems. The ability of cells to produce plasmin on their surface, due to the presence of uPA and plasminogen receptors, is at the basis of the regulation of the plasminogen activating system in vivo. Synthesis, activity and localization of each component can be individually regulated thus providing the system with an enormous flexibility.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2151734

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  24 in total

Review 1.  Active cell death in hormone-dependent tissues.

Authors:  M P Tenniswood; R S Guenette; J Lakins; M Mooibroek; P Wong; J E Welsh
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

2.  Role of distinct mitogen-activated protein kinase pathways and cooperation between Ets-2, ATF-2, and Jun family members in human urokinase-type plasminogen activator gene induction by interleukin-1 and tetradecanoyl phorbol acetate.

Authors:  G Cirillo; L Casalino; D Vallone; A Caracciolo; D De Cesare; P Verde
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

3.  Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbol-ester.

Authors:  P Rørth; C Nerlov; F Blasi; M Johnsen
Journal:  Nucleic Acids Res       Date:  1990-09-11       Impact factor: 16.971

4.  Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.

Authors:  D Samid; S Shack; C E Myers
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

5.  Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis.

Authors:  P Dell'Era; M Mohammadi; M Presta
Journal:  Mol Biol Cell       Date:  1999-01       Impact factor: 4.138

6.  Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples.

Authors:  M R Emmert-Buck; M J Roth; Z Zhuang; E Campo; J Rozhin; B F Sloane; L A Liotta; W G Stetler-Stevenson
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

7.  Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

Authors:  P Carmeliet; J M Stassen; L Schoonjans; B Ream; J J van den Oord; M De Mol; R C Mulligan; D Collen
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

8.  Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.

Authors:  P Carmeliet; L Kieckens; L Schoonjans; B Ream; A van Nuffelen; G Prendergast; M Cole; R Bronson; D Collen; R C Mulligan
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

9.  Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK.

Authors:  C Takahashi; Z Sheng; T P Horan; H Kitayama; M Maki; K Hitomi; Y Kitaura; S Takai; R M Sasahara; A Horimoto; Y Ikawa; B J Ratzkin; T Arakawa; M Noda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

10.  Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function.

Authors:  Hua Fang; Veronica R Placencio; Yves A DeClerck
Journal:  J Natl Cancer Inst       Date:  2012-09-13       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.